OUR MISSION

We strive to treat more patients with ground-breaking therapies. This mission inspires and motivates us.

STRATEGY FOR VALUE CREATION

Actelion’s strategy is designed to create value by leveraging the Company’s many strengths. These include its global leadership in the field of pulmonary arterial hypertension (PAH) therapy, a strong and effective worldwide specialty commercial organization, a highly productive discovery capability and a unique company culture that focuses on delivering innovative medicines that improve patient’s lives.

We are the leaders in PAH therapy and, with our PAH products, we will continue to lead well into the future. During this time we must build our portfolio – through R&D and/or business development, to find additional meaningfully differentiated products to benefit patients. To realize our potential, we need to have a solid business – which means never losing sight of spending, whilst maintaining quality in all that we do.

Strategic principles

 
Actelion - Shaping Our Future

Strategic Principles

Total employees

Drug Discovery388
Clinical Development452
Marketing & Sales1,443
Support Functions341
Total2,624
December  2016

Shareprice

ATLN SIX Swiss Exchange

Shareprice
At 09:08:59 CET 24/04/2017
CHF 282,60Up Down image
+2,60 (+0,93%)
 

Project Manager, Drug Regulatory Affairs 

 

"I enjoy working for Actelion because innovation is not just in the science; it's a part of everything that we do in all departments to bring meaningful drugs to patients."